Research Team

Researchers within the Division of Transplantation at the University of Maryland Medical Center are committed to investigating new ways to advance the science of transplantation and ensure better futures for patients in need of transplant or for those who are already living with organ transplants.

The research within the Division of Transplantation falls into several categories:

  • Inducing tolerance - teaching the body to accept a foreign graft, such as a transplanted organ, without rejection and with limited or no immunosuppression.
  • Immunosuppression medications and medication management - testing the latest medications or combinations of medications to prevent rejection while reducing the "pill burden" on patients and creating protocols that demonstrate long-term success with fewer side effects.
  • Increasing the number of available donor organs - through tissue regeneration and systematic sourcing of available organs.
  • Advancements in surgical technique - use of new operative tools, materials and techniques, including the single-incision laparoscopic surgery used on living kidney donors.
  • Using bone marrow-derived stem cells to decrease rejection - could help eliminate need for immunosuppression in all types of organ recipients.
  • Bridge-to-transplant technology - medical devices used to help patients who are in need of transplant but either not at the top of the wait list or without an available donor organ.

Transplants & COVID-19 Vaccines

The University of Maryland is leading a trial to learn more about how well COVID-19 vaccines work in transplant recipients, and in those waiting for a transplant. See if you are a candidate for the trial.

Research in Lung Healing

Clinicians and scientists are invested in improving the outcomes of patients with acute and chronic lung diseases. Research is being conducted through the Lung Healing Program, both in laboratory settings and with UMMC patients who could benefit from the latest in lung disease treatment.

Collaborators in the Lung Healing Program include cardiothoracic surgeons, critical care doctors, trauma surgeons, nurses within these specialty areas, and researchers from the University of Maryland School of Medicine.

Learn more about ongoing research within the Lung Healing Program.

Advances in Hepatitis C Treatment

University of Maryland Medical Center (UMMC) is one of the country's premier hospitals treating patients with liver failure. Our doctors and researchers help to discover new medications and treatment options for many liver diseases, including hepatitis C.

Today, the U.S. Food and Drug Administration (FDA) is approving new medications that will treat cirrhosis of the liver faster, easier and more effectively in patients with liver damage caused by chronic hepatitis C.

Tissue Engineering

Basic, Translational, and Clinical Research and Trials